Rodent home cage monitoring for preclinical safety pharmacology assessment: results of a multi-company validation evaluating nonclinical and clinical data from three compounds
We showed that the methodology fits well with standard study designs. More importantly we uncovered significant findings in all three compounds that were not observed in the original classic safety pharmacology tests. The lack of such effects observed in standard preclinical assessment likely reflects functional differences between the limited observational snapshots characteristic of this approach and the more comprehensive temporal resolution enabled by continuous home cage monitoring.
Authors
- Justin Sutherland (ORCID: https://orcid.org/0000-0001-5375-6846)
- Ann Holmes (ORCID: https://orcid.org/0000-0002-2418-1710)
- J. Douglas Armstrong (ORCID: https://orcid.org/0000-0002-5397-3864)
- Chiara Giuliano (ORCID: https://orcid.org/0000-0002-4597-8753)
- Michelle McClafferty
- Aileen Milne
- Rowland R. Sillito (ORCID: https://orcid.org/0009-0008-6760-5107)
- Michael G. Rolf
- Aleena Mary Cherian (ORCID: https://orcid.org/0000-0002-5102-9116)
- Eric I. Rossman (ORCID: https://orcid.org/0000-0002-5285-6754)
- Greet Teuns
- C. Sigfridsson
Institutions
- Johnson & Johnson (United States) (US)
- Charles River Laboratories (United Kingdom) (GB)
- GlaxoSmithKline (United States) (US)
- Imperial Consultants (GB)
- National Centre for the Replacement Refinement and Reduction of Animals in Research (GB)
- AstraZeneca (Sweden) (SE)
- AstraZeneca (Germany) (DE)
- University of Edinburgh (GB)
Publication Details
- Journal
- Frontiers in Toxicology
- Published
- 2025-11-05
- DOI
- https://doi.org/10.3389/ftox.2025.1655330
- Citations
- 1
- Primary Topic
- Immunotoxicology and immune responses
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- AstraZeneca
- GlaxoSmithKline
- University of Oxford